Related Experiment Video
Updated: May 11, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Current and future disease progression of the chronic HCV population in the United States
Martin Zalesak1, Kevin Francis, Alex Gedeon
1Trinity Partners, LLC, Waltham, Massachusetts, United States of America. zalesakm@trinitypartners.com
Insights
Chronic hepatitis C virus (HCV) infection significantly impacts the "baby boomer" generation, driving advanced liver disease (AdvLD) progression. Urgent diagnosis and treatment are crucial to interrupt disease advancement in this population.
Area of Science:
- Hepatology
- Public Health
- Epidemiology
Background:
- Chronic hepatitis C virus (HCV) infection is a leading cause of advanced liver disease (AdvLD), including cirrhosis and liver cancer.
- The
- baby boomer
- generation (born 1945-1964) represents a disproportionately large segment of the HCV-infected population and associated healthcare costs.
Purpose of the Study:
- To determine historical rates of HCV patient progression to AdvLD.
- To project the prevalence of AdvLD through 2015.
- To identify key demographic groups driving AdvLD progression and costs.
Main Methods:
- Utilized National Health and Nutrition Examination Surveys for 2008 US chronic HCV prevalence.
- Analyzed 2007-2009 IMS LifeLink and CMS Medicare claims data for disease progression and costs.
- Developed a projection model for AdvLD prevalence through 2015, incorporating diagnosed and undiagnosed patients.
Main Results:
- The diagnosed chronic HCV population increased from 983,000 to 1.19 million between 2007-2009.
- Patients born 1945-1964 constituted 75.0% of all HCV patients, 83.7% of AdvLD patients, and 79.2% of costs in 2009.
- AdvLD population projected to grow from 195,000 (2008) to 601,000 (2015), with 73.5% of new cases from undiagnosed individuals.
Conclusions:
- HCV is primarily a disease affecting the
- baby boomer
- population, with significant AdvLD progression and associated costs.
- A substantial increase in AdvLD is projected, driven by both diagnosed and undiagnosed HCV cases.
- Immediate strategies for HCV diagnosis and treatment are essential to mitigate AdvLD progression, particularly in the baby boomer cohort.
Abstract:
Chronic hepatitis C virus (HCV) infection can lead to advanced liver disease (AdvLD), including cirrhosis, decompensated cirrhosis, and liver cancer. The aim of this study was to determine recent historical rates of HCV patient progression to AdvLD and to project AdvLD prevalence through 2015. We first determined total 2008 US chronic HCV prevalence from the National Health and Nutrition Evaluation Surveys. Next, we examined disease progression and associated non-pharmacological costs of diagnosed chronic HCV-infected patients between 2007-2009 in the IMS LifeLink and CMS Medicare claims databases. A projection model was developed to estimate AdvLD population growth through 2015 in patients diagnosed and undiagnosed as of 2008, using the 2007-2009 progression rates to generate a "worst case" projection of the HCV-related AdvLD population (i.e., scenario where HCV treatment is the same in the forecasted period as it was before 2009). We found that the total diagnosed chronic HCV population grew from 983,000 to 1.19 million in 2007-2009, with patients born from 1945-1964 accounting for 75.0% of all patients, 83.7% of AdvLD patients, and 79.2% of costs in 2009, indicating that HCV is primarily a disease of the "baby boomer" population. Non-pharmacological costs grew from $7.22 billion to $8.63 billion, with the majority of growth derived from the 60,000 new patients that developed AdvLD in 2007-2009, 91.5% of whom were born between 1945 and 1964. The projection model estimated the total AdvLD population would grow from 195,000 in 2008 to 601,000 in 2015, with 73.5% of new AdvLD cases from patients undiagnosed as of 2008. AdvLD prevalence in patients diagnosed as of 2008 was projected to grow 6.5% annually to 303,000 patients in 2015. These findings suggest that strategies to diagnose and treat HCV-infected patients are urgently needed to increase the likelihood that progression is interrupted, particularly for patients born from 1945-1964.
Related Concept Videos
Hepatitis
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Cirrhosis II: Pathophysiology
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Viral Hepatitis I: Introduction
